Cargando…
Differential Inhibition of LRRK2 in Parkinson's Disease Patient Blood by a G2019S Selective LRRK2 Inhibitor
BACKGROUND: A common genetic mutation that causes Parkinson's disease (PD) is the G2019S LRRK2 mutation. A precision medicine approach that selectively blocks only excess kinase activity of the mutant allele could yield a safe and effective treatment for G2019S LRRK2 PD. OBJECTIVE: To determine...
Autores principales: | Bright, Jessica M., Carlisle, Holly J., Toda, Alyssa M. A., Murphy, Molly, Molitor, Tyler P., Wren, Paul, Andruska, Kristin M., Liu, Enchi, Barlow, Carrolee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248170/ https://www.ncbi.nlm.nih.gov/pubmed/33836114 http://dx.doi.org/10.1002/mds.28490 |
Ejemplares similares
-
Coding and Noncoding Variation in
LRRK2
and Parkinson's Disease Risk
por: Lake, Julie, et al.
Publicado: (2021) -
Differential Phospho‐Signatures in Blood Cells Identify
LRRK2 G2019S Carriers in Parkinson's Disease
por: Garrido, Alicia, et al.
Publicado: (2022) -
Functional Analyses of Two Novel
LRRK2
Pathogenic Variants in Familial Parkinson′s Disease
por: Coku, Ilda, et al.
Publicado: (2022) -
Structural Biology of LRRK2 and its Interaction with Microtubules
por: Leschziner, Andres E., et al.
Publicado: (2021) -
LRRK2 dephosphorylation increases its ubiquitination
por: Zhao, Jing, et al.
Publicado: (2015)